Dokumentdetails
ID
oai:pubmedcentral.nih.gov:8132...
Thema
ArticleAutor
Walti, Carla S. Loes, Andrea N. Shuey, Kiel Krantz, Elizabeth M. Boonyaratanakornkit, Jim Keane-Candib, Jacob Loeffelholz, Tillie Wolf, Caitlin R. Taylor, Justin J. Gardner, Rebecca A. Green, Damian J. Cowan, Andrew J. Maloney, David G. Turtle, Cameron J. Pergam, Steven A. Chu, Helen Y. Bloom, Jesse D. Hill, Joshua A.Langue
enEditor
Cold Spring Harbor Laboratory
Kategorie
medrxiv
Jahr
2021
Auflistungsdatum
16.08.2021
Schlüsselwörter
influenza time b-cell baseline ≥1 antibody immunogenicity responses therapyZusammenfassung
Recipients of chimeric antigen receptor-modified T (CAR-T) cell therapies for B-cell malignancies are immunocompromised and at risk for serious infections.
Vaccine immunogenicity is unknown in this population.
We conducted a prospective observational study of the humoral immunogenicity of 2019–2020 inactivated influenza vaccines (IIV) in children and adults immediately prior to (n=7) or 13–57 months after (n=15) CD19-, CD20-, or BCMA-targeted CAR-T-cell therapy, as well as controls (n=8).
Individuals post-CAR-T-cell therapy were in remission.
We tested for antibodies to 4 vaccine strains at baseline and ≥1 time point after IIV using neutralization and hemagglutination inhibition assays.
An antibody response was defined as a ≥4-fold titer increase from baseline at the first post-vaccine time point.
Baseline A(H1N1) titers in the CAR-T cohorts were significantly lower compared to controls.
Antibody responses to ≥1 vaccine strain occurred in 2 (29%) individuals before CAR-T-cell therapy; one individual maintained a response for >3 months post-CAR-T-cell therapy.
Antibody responses to ≥1 vaccine strain occurred in 6 (40%) individuals vaccinated after CAR-T-cell therapy.
An additional 2 (29%) and 6 (40%) individuals had ≥2-fold increases (at any time) in the pre- and post-CAR-T cohorts, respectively.
There were no identified clinical or immunologic predictors of antibody responses.
Neither severe hypogammaglobulinemia nor B-cell aplasia precluded antibody responses.
These data support consideration for vaccination before and after CAR-T-cell therapy for influenza and other relevant pathogens such as SARS-CoV-2, irrespective of hypogammaglobulinemia or B-cell aplasia.
Larger studies are needed to determine correlates of vaccine immunogenicity and durability in CAR-T-cell therapy recipients.
Walti, Carla S.,Loes, Andrea N.,Shuey, Kiel,Krantz, Elizabeth M.,Boonyaratanakornkit, Jim,Keane-Candib, Jacob,Loeffelholz, Tillie,Wolf, Caitlin R.,Taylor, Justin J.,Gardner, Rebecca A.,Green, Damian J.,Cowan, Andrew J.,Maloney, David G.,Turtle, Cameron J.,Pergam, Steven A.,Chu, Helen Y.,Bloom, Jesse D.,Hill, Joshua A., 2021, Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy, Cold Spring Harbor Laboratory
Configurable Safety Tuning of Language Models with Synthetic Preference Data
data preference cst dpo configurable language safety
Affective flexibility as a developmental building block of cognitive reappraisal: An fMRI study
cognitive success affective flexibility
